CoreWeave Earnings Ahead Of Q2 Report

CoreWeave earnings preview Q2 results due Aug. 11, 2026, as investors weigh backlog conversion, AI capex and new financing for cloud expansion.

August 11, 2026·2 min read
View all news articles
Flat filled vector of a GPU rack straining under contracted orders, evoking CoreWeave earnings focus on backlog conversion.

KEY TAKEAWAYS

  • Guided Q2 revenue $2.5B to $2.6B and reported a $99.4B contracted backlog.
  • Closed a $2.6B delayed-draw loan and raised 2026 capex floor to $31B.
  • Investors will watch backlog conversion and deployment efficiency as the path to profitability.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

CoreWeave, Inc. (CRWV) will report second-quarter 2026 results after the market close on Aug. 11, 2026. Investors will focus on whether the company can convert its massive contracted backlog and recent financing into cash as it accelerates AI data-center deployments.

Earnings, Guidance, and Backlog Conversion

Sell-side estimates for CoreWeave’s Q2 revenue range from $2.5 billion to $2.56 billion, up roughly 111% from $1.21 billion a year earlier. Consensus expects an adjusted loss per share between $1.17 and $1.23. These projections reflect strong AI compute demand but challenge management to show improving margins and cash flow amid rapid growth.

In its Q1 2026 filing, CoreWeave guided Q2 revenue between $2.45 billion and $2.60 billion and full-year 2026 revenue of $12 billion to $13 billion. It forecast adjusted operating income of $30 million to $90 million for Q2 and $900 million to $1.1 billion for the full year. The company reported a contracted revenue backlog of $99.4 billion at the end of Q1 2026. This backlog and guidance frame investor expectations on how quickly contracted commitments can translate into revenue and cash flow.

Financing, Capital Spending, and Insider Activity

On Aug. 10, 2026, CoreWeave announced it closed a $2.6 billion delayed draw term loan facility to support AI cloud expansion and committed customer deployments. The company linked the financing to ongoing AI infrastructure demand and these deployments. This facility reduces near-term funding pressure, shifting investor focus to management’s ability to deploy capacity efficiently and realize contracted revenue.

SEC Form 4 filings show CEO Michael Intrator sold about 307,692 Class A shares on Aug. 4 under a Rule 10b5-1 trading plan adopted on Nov. 20, 2025. The prearranged plan clarifies that the sales were scheduled in advance.

Preview reports indicate CoreWeave raised the low end of its 2026 capital-expenditure range to $31 billion from $30 billion, while maintaining the upper end at $35 billion. This scale of spending will be critical to meeting customer commitments and converting backlog into revenue and cash.

Together, the company’s guidance, financing, and backlog focus investor attention on execution. The key near-term test is whether management can turn contracted commitments into revenue and cash while sustaining aggressive capital spending. Previews suggest profitability remains months away, emphasizing deployment execution as the central challenge ahead of the earnings release.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Plug Power Q2 Results Lift Margins, Raise Outlook

Plug Power Q2 Results Lift Margins, Raise Outlook

Plug Power Q2 results show margin gains and raised revenue guidance, but big losses and planned asset sales leave liquidity execution the key trader risk.

AST SpaceMobile Q2 Results Miss Estimates, Reaffirm Guidance

AST SpaceMobile Q2 Results Miss Estimates, Reaffirm Guidance

AST SpaceMobile Q2 results missed expectations; management reaffirmed 2026 revenue guidance and pointed to a $1.3B backlog as traders weigh cash burn risk.

Cardinal Health Earnings Lift Guidance on Specialty Drugs

Cardinal Health Earnings Lift Guidance on Specialty Drugs

Cardinal Health earnings raised full-year EPS guidance to $12.40 to $12.60 on specialty drug strength, likely prompting repositioning into specialty names.

Super Micro Earnings Preview: Margins and Backlog

Super Micro Earnings Preview: Margins and Backlog

Super Micro earnings preview noted 15%-17% gross margin and a record backlog, putting traders on watch for backlog conversion into revenue and AI demand.

Trump Media Earnings: Q2 Loss Deepens

Trump Media Earnings: Q2 Loss Deepens

Trump Media earnings said non-cash digital-asset writedowns pushed $238.1 million Q2 loss, magnifying asset-price volatility and prompting traders to trim stakes.

Nvidia $500 Billion AI Financing Deal

Nvidia $500 Billion AI Financing Deal

Nvidia $500 billion AI financing pact with six Wall Street firms aims to mobilize capital for compute and data centers and could reprice chip demand.